Home / Congress Presentations / C3G and Primary IC-MPGN / National Organization for Rare Disorders (NORD) 2025
Landing
National Organization for Rare Disorders (NORD) 2025
Pegcetacoplan for adolescents with C3G or primary (idiopathic) IC-MPGN in the phase 3 VALIANT study
VALIANT: One year of pegcetacoplan for C3G or primary (idiopathic) IC-MPGN
Care coordination is a considerable challenge facing patients with C3 glomerulopathy and their care partners
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.